BlackRock Maintains 15.6% Stake in Tandem Diabetes Care (TNDM)
Ticker: TNDM · Form: SC 13G/A · Filed: Jan 23, 2024 · CIK: 1438133
| Field | Detail |
|---|---|
| Company | Tandem Diabetes Care Inc (TNDM) |
| Form Type | SC 13G/A |
| Filed Date | Jan 23, 2024 |
| Risk Level | low |
| Sentiment | bullish |
Complexity: simple
Sentiment: bullish
Topics: institutional-ownership, passive-investment, amendment, healthcare
TL;DR
**BlackRock still owns 15.6% of TNDM, a bullish sign for the stock.**
AI Summary
BlackRock Inc. has updated its ownership stake in Tandem Diabetes Care Inc. (TNDM) as of December 31, 2023, filing an amendment to its Schedule 13G. This filing indicates BlackRock's passive investment in the medical device company, holding 10,035,765 shares, which represents 15.6% of the common stock. This matters to investors because BlackRock is a major institutional investor, and its continued significant stake signals confidence in Tandem Diabetes Care's long-term prospects, potentially influencing other investors.
Why It Matters
BlackRock's substantial, continued ownership in Tandem Diabetes Care Inc. suggests institutional confidence in the company's future, which can be a positive signal for current and prospective shareholders.
Risk Assessment
Risk Level: low — This filing indicates a passive, significant institutional ownership, which generally reduces volatility and adds stability to the stock.
Analyst Insight
A smart investor would view BlackRock's continued significant stake as a vote of confidence, potentially indicating long-term stability and growth prospects for Tandem Diabetes Care Inc., and might consider further research into the company's fundamentals.
Key Numbers
- 10,035,765 — Shares Owned (Represents BlackRock's total beneficial ownership in Tandem Diabetes Care Inc.)
- 15.6% — Percentage of Class (Indicates BlackRock's significant stake in Tandem Diabetes Care Inc.'s common stock.)
- 875372203 — CUSIP Number (Identifies the specific class of securities (Common Stock) of Tandem Diabetes Care Inc.)
Key Players & Entities
- BlackRock Inc. (company) — the reporting person and institutional investor
- Tandem Diabetes Care Inc. (company) — the subject company whose securities are being reported
- 10,035,765 (dollar_amount) — number of shares beneficially owned by BlackRock Inc.
- 15.6% (dollar_amount) — percentage of class owned by BlackRock Inc.
- December 31, 2023 (date) — the date of the event requiring this filing
Forward-Looking Statements
- BlackRock will maintain a significant, passive stake in Tandem Diabetes Care Inc. throughout 2024. (BlackRock Inc.) — high confidence, target: December 31, 2024
FAQ
Who is the reporting person in this SC 13G/A filing?
The reporting person is BlackRock, Inc., as stated in item (1) of the cover page and the 'FILED BY' section of the filing.
What is the subject company whose securities are being reported?
The subject company is TANDEM DIABETES CARE INC, as indicated in the 'SUBJECT COMPANY' section and the 'Name of Issuer' on the Schedule 13G.
What percentage of Tandem Diabetes Care Inc.'s common stock does BlackRock Inc. beneficially own as of the filing date?
As of December 31, 2023, BlackRock Inc. beneficially owns 15.6% of Tandem Diabetes Care Inc.'s common stock, as detailed in the filing.
What is the CUSIP number for the class of securities reported in this filing?
The CUSIP number for the Common Stock of Tandem Diabetes Care Inc. is 875372203, as listed on the cover page of the Schedule 13G.
What was the date of the event which required the filing of this statement?
The date of the event which required the filing of this statement was December 31, 2023, as specified on the Schedule 13G.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 23, 2024 regarding TANDEM DIABETES CARE INC (TNDM).